Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12
Open accessAbstract
Background The beneficial effect of intravitreal ranibizumab in the treatment of neovascular age-related macula degeneration (nAMD) is well known. Outcome data for eyes presenting with visual acuity better than 6/12 is limited.Aims To assess the effect of baseline vision on outcome in ranibizumab-treated nAMD eyes, including a subgroup with baseline vision ≥6/12 (<0.30 logmar).Design Prospective, consecutive and interventional case series.Methods A consecutive cohort of patients treated with intravitreal ranibizumab for nAMD with 52-week follow-up were studied. Patients who had received previous treatment for nAMD were excluded. Eyes were stratified according to baseline logmar visual acuity into four groups: <0.30 (>6/12), 0.30-0.59 (6/12-6/24), 0.60-0.99 (6/24-6/60) and 1.00-1.20 (6/60-6/96). Intravitreal ranibizumab (0.5 mg in 0.05 ml) was administered in three loading monthly doses followed by PRN dosing according to optical coherence tomography (OCT) findings.Results A total of 615 eyes were studied including 88 eyes with baseline vision <0.30. The mean change in logmar letters at 52 weeks was +5.5 (entire study group), -0.5 (<0.30 subgroup), +2.2 (0.30-0.59 subgroup), +6.5 (0.60-0.99 subgroup) and +15.3 (1.00-1.20 subgroup). In the <0.30 subgroup, 60 of 88 eyes (68%) had best-corrected visual acuity (BCVA) equal to or better than baseline and 82 of 88 eyes (93%) lost <15 letters at 52 weeks. Within this subgroup 56 of 67 eyes (84%) maintained UK driving standard BCVA visual acuity over the study period.Conclusions This study provides evidence that intravitreal ranibizumab treatment stabilises good vision in nAMD presenting with vision better than 6/12 over 52 weeks follow-up.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The degree of change in visual acuity depends on the baseline acuity at the time treatment is initiated.
“The degree of change in VA is contingent on the baseline acuity, that is, at the time-point at which treatment is initiated.16,[19][20][21]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 12 · Cited by 50
Research works printed but not linked: 3
- [4]4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
- [14]14. Boyer DS, Antoszyk AN, Awh OC, Bhisitkul RB, Shapiro H, Archarya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age related macular degeneration. Ophthalmology 2007; 114: 246-252.
- [16]16. Pieramici DJ, Bressler SB, Koester JM, Bressler NM. Occult with no classic subfoveal CNV in age-related macula degeneration. Clinically relevant natural history information in larger lesions with good vision from Verteporfin in Photodynamic Therapy VIP trial: VIP report no 4. Arch Ophthalmol 2006; 124: 660-664.
- Authors
- Williams, T. A., & Blyth, C. P.
- Affiliations
- University Hospital of Wales (GB)
- Royal Gwent Hospital (GB)
- Corresponding author
- Williams, T A
- Venue
- Eye
- Published
- 2011-09-16
- Volume
- 25
- Issue
- 12
- Pages
- 1617-1621
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC3234468
- OpenAlex
- W2008299291
- Cited by
- 50
- References
- 12
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 8 · 2013: 6 · 2012: 4
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Eye (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, baseline visual acuity, intravitreal anti-VEGF therapy, visual acuity outcomes, treatment outcome prediction, best-corrected visual acuity, retinal pigment epithelium thickness
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Female, Humans, Immunologic Factors, Macular Degeneration, Male, Middle Aged, Prospective Studies, Visual Acuity, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
